Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 6/20 | 0.73 |
| ▸ | CNR1 | P21554 | 8/20 | 0.63 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883575 | 0.91 | GRIK1 (0.70) | GRIK1KCNMA1CA12CA1CA2 | |
| SCHEMBL5594888 | 0.88 | HDAC1 (0.67) | GRIK1CNR1CA12CA1CA2 | |
| SCHEMBL1883373 | 0.88 | CA12 (0.71) | GRIK1KCNMA1CA12CA1CA2 | |
| SCHEMBL4358450 | 0.85 | CA12 (0.68) | GRIK1KCNMA1CA12CA1CA2 | |
| SCHEMBL3957387 | 0.84 | GRIK1 (1.00) | GRIK1 | |
| SCHEMBL20557568 | 0.83 | CNR1 (0.81) | GRIK1CNR1 | |
| SCHEMBL28295632 | 0.83 | KCNMA1 (0.68) | GRIK1KCNMA1CA12CA1CA2 | |
| SCHEMBL420364 | 0.82 | GRIK1 (0.80) | GRIK1CNR1 | |
| SCHEMBL17316238 | 0.81 | CA12 (0.59) | GRIK1KCNMA1CA12CA1CA2 | |
| SCHEMBL1882786 | 0.80 | NTRK1 (0.60) | GRIK1KCNMA1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | US | claimed |
| US-20070142450-A1 | Novel urea derivatives and their medical use | NEUROSEARCH A/S (DK) | 2007-06-21 | — | — | US | claimed |
| EP-2255848-A2 | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | NeuroSearch AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20070142450-A1 | Novel urea derivatives and their medical use | NEUROSEARCH A/S (DK) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | CHRNA10, CHRNA4, CHRNA5 | GRIK1 46/4885CNR1 99/4885KCNMA1 587/4885 |
| US-20070142450-A1 | Novel urea derivatives and their medical use | ACHE, NMUR1, NMUR2 | GRIK1 1260/4885CNR1 32/4885KCNMA1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.